Zhejiang Huahai Pharmaceutical (600521.SH) has obtained the drug registration certificate for Naloxone Hydrochloride Injection.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of naloxone hydrochloride injection. Indications for naloxone hydrochloride injection include: 1. Used for opioid anesthesia postoperatively, to counteract respiratory depression caused by such drugs and to promote patient recovery; 2. Used for opioid overdose to partially or completely reverse respiratory depression caused by opioids; 3. For the rescue of acute ethanol poisoning; 4. Used for the diagnosis of acute opioid overdose.